A meta-analysis of the relationship between CD133 expression, prognosis, and clinical and pathological features of ovarian cancer showed that, unlike CD44, high CD133 expression correlates with a worse prognosis in patients [65]. The gene discussed is PROM1; the disease is ovarian carcinoma.